In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
After finishing at $0.83 in the prior trading day, Atossa Therapeutics Inc (NASDAQ: ATOS) closed at $0.84, up 0.93%. In other words, the price has increased by $0.93 from its previous closing price. On the day, 0.59 million shares were traded.
Ratios:
Our goal is to gain a better understanding of ATOS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 13.30 and its Current Ratio is at 13.30. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Maxim Group on January 26, 2018, initiated with a Buy rating and assigned the stock a target price of $2.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 10 ’24 when Finn Jonathan bought 25,000 shares for $1.77 per share. The transaction valued at 44,250 led to the insider holds 25,000 shares of the business.
Stock Price History:
Over the past 52 weeks, ATOS has reached a high of $2.31, while it has fallen to a 52-week low of $0.72. The 50-Day Moving Average of the stock is -12.06%, while the 200-Day Moving Average is calculated to be -33.73%.
Shares Statistics:
A total of 125.80M shares are outstanding, with a floating share count of 125.75M. Insiders hold about 0.04% of the company’s shares, while institutions hold 28.40% stake in the company.
Earnings Estimates
A detailed examination of Atossa Therapeutics Inc (ATOS) is currently in progress, with 3.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.06, with high estimates of -$0.06 and low estimates of -$0.07.
Analysts are recommending an EPS of between -$0.21 and -$0.22 for the fiscal current year, implying an average EPS of -$0.22. EPS for the following year is -$0.27, with 3.0 analysts recommending between -$0.25 and -$0.3.
